Merck KGAA: Reinventing the Mid-Sized Public Company
Executive Summary
Merck's goal is to build a leading position in specialty OTCs as well as a worldwide generics business, both goals designed to offset the risks of its R&D program. Its new business allows it to use its size as an advantage against smaller, specialized players while avoiding direct competition with the larger multinationals.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.